AstraZeneca has said it has "no idea" where rumours of a plan to relocate a planned facility in the UK to the US have come from, adding: "They do not seem to be based on facts."
AstraZeneca's EGFR inhibitor Tagrisso has become the go-to therapy for EGFR-mutated non-small cell lung cancer (NSCLC), but now has competition from Johnson & Johnson's Rybrevant and La
The EMA has started a review of AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC) that could see the drug being used in advanced breast cancer with even lower levels of the HER
AstraZeneca has claimed FDA approval for its immunotherapy Imfinzi before and after surgery for non-small cell lung cancer, setting up a contest with MSD's rival Keytruda.
AstraZeneca's plan to invest £450 million ($578 million) in a vaccines manufacturing plant in the UK has been thrown into doubt, claims a report in the Financial Times.
AstraZeneca has become the first company to get approval for the combination of an immunotherapy with a PARP inhibitor for treating endometrial cancer.